Notas de prensa
Volver a la página anterior
 


News Release
September 28, 2015
Contact: Jill DeCoste
Phone: +1 978-715-4670
Email: jill.decoste@emdmillipore.com

Merck Millipore Publishes White Paper Highlighting Importance of Emerging Biotech Companies for Discovery of New Drugs During Recent Emerging Biotech Executive Summit
  • Paper focuses on strategies to advance molecules and bring lifesaving drugs to market faster
  • Purpose is to encourage and continue open dialogue around investments, partnerships and building value on the road to clinic
  • Summit sessions led by executives in alliance management, in-licensing and venture funding

September 28, 2015, Darmstadt, Germany — Merck Millipore, the Life Science division of Merck, today announced that it has published an original white paper, recognizing the impact the emerging biotech community has on the future of healthcare.

The paper is based on discussions during the company’s Emerging Biotech Executive Summit on June 15, 2015 in Philadelphia. At the event, forty biotech leaders from across the USA, representing over one hundred molecules, came together to have an open dialogue around the emerging biotech community, early-stage investments and partnerships as well as how to build value, credibility, and recognition on the road to clinic. This white paper builds upon that discussion.

As a partner of the life science industry, Merck Millipore recognizes the impact the emerging biotech community has on the future of healthcare. Udit Batra, President and CEO of Merck Millipore, reinforced the company’s commitment to this community during his opening presentation at the summit.

“Emerging biotech companies are a critical component and source of innovation, helping to bring groundbreaking drug products to market. These companies could capture a much higher share of value by bringing new molecules further along the development track,” says Batra.

By building upon the panel discussions that were initiated at the summit, Merck Millipore’s new white paper provides insights from executives in alliance management, in-licensing and venture funding around the challenges that these companies face, including limited capabilities, expertise and funding, and insight on how to conquer them. It is a valuable source of information for any emerging biotech firm looking for strategies of how to best push their molecules through the pipeline and ultimately to market.

Visit www.merckmillipore.com/ebsummit to download the white paper.

About Merck Millipore
Merck Millipore is the Life Science subsidiary of Merck, Darmstadt, Germany. As part of the global Life Science business of Merck, Merck Millipore offers a broad range of innovative performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.

About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono. Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit www.merckserono.com.

About Merck
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

For more information, please visit www.merckgroup.com